Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $908.83 | 9 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $270.94 | 2 | $0 (2024) |
| Gilead Sciences, Inc. | $125.00 | 1 | $0 (2022) |
| Celgene Corporation | $115.85 | 1 | $0 (2019) |
| GENZYME CORPORATION | $115.57 | 1 | $0 (2020) |
| Incyte Corporation | $110.36 | 1 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $82.61 | 1 | $0 (2024) |
| BeiGene USA, Inc. | $70.29 | 1 | $0 (2024) |
| Stemline Therapeutics Inc. | $18.21 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $307.05 | 4 | AstraZeneca Pharmaceuticals LP ($135.94) |
| 2023 | $135.00 | 1 | AstraZeneca Pharmaceuticals LP ($135.00) |
| 2022 | $125.00 | 1 | Gilead Sciences, Inc. ($125.00) |
| 2021 | $110.36 | 1 | Incyte Corporation ($110.36) |
| 2020 | $115.57 | 1 | GENZYME CORPORATION ($115.57) |
| 2019 | $115.85 | 1 | Celgene Corporation ($115.85) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug), SCEMBLIX | Food and Beverage | In-kind items and services | $82.61 | General |
| Category: Immunology | ||||||
| 07/30/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $18.21 | General |
| Category: Oncology | ||||||
| 06/02/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $135.94 | General |
| Category: Oncology | ||||||
| 06/01/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $70.29 | General |
| Category: Oncology | ||||||
| 06/03/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Oncology | ||||||
| 12/10/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 07/16/2021 | Incyte Corporation | PEMAZYRE (Drug) | Food and Beverage | Cash or cash equivalent | $110.36 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 02/20/2020 | GENZYME CORPORATION | MOZOBIL (Drug) | Food and Beverage | In-kind items and services | $115.57 | General |
| Category: Oncology | ||||||
| 12/07/2019 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $115.85 | General |
| Category: Hematology / Oncology | ||||||
About Dr. Muhammad Salman Faisal, MD
Dr. Muhammad Salman Faisal, MD is a Hematology & Oncology healthcare provider based in Oklahoma City, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/25/2017. The National Provider Identifier (NPI) number assigned to this provider is 1295258911.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Muhammad Salman Faisal, MD has received a total of $908.83 in payments from pharmaceutical and medical device companies, with $307.05 received in 2024. These payments were reported across 9 transactions from 8 companies. The most common payment nature is "Food and Beverage" ($908.83).
Practice Information
- Specialty Hematology & Oncology
- Location Oklahoma City, OK
- Active Since 07/25/2017
- Last Updated 11/04/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1295258911
Products in Payments
- CALQUENCE (Drug) $270.94
- Pomalyst (Drug) $115.85
- MOZOBIL (Drug) $115.57
- PEMAZYRE (Drug) $110.36
- Fabhalta (Drug) $82.61
- BRUKINSA (Drug) $70.29
- Orserdu (Drug) $18.21
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Oklahoma City
Robert Reynolds, Md, MD
Hematology & Oncology — Payments: $14,579
Philip Comp, Md, MD
Hematology & Oncology — Payments: $13,151
Dr. Charles Hollen, M.d, M.D
Hematology & Oncology — Payments: $12,135
Jennifer Holter-Chakrabarty, Md, MD
Hematology & Oncology — Payments: $11,994
Dr. Saadia Chohan, Md, MD
Hematology & Oncology — Payments: $11,197
Abby Bova, Md, MD
Hematology & Oncology — Payments: $5,791